Long-Term follow-up of GH-treated girls with turner syndrome: BMI, blood pressure, body proportions

Hormone Research

Volumn 71, Issue 6, 2009, Pages 336-340

  Bannink, Ellen M N ^a   Van Der Palen, Roel L F ^a   Mulder, Paul G H ^b   De Muinck Keizer Schrama, Sabine M P F ^a,b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Blood pressure; Body mass index; Body proportions; Follow up after GH therapy; Growth hormone therapy; Turner syndrome

Indexed keywords

ESTRADIOL; GESTAGEN; HUMAN GROWTH HORMONE;

ADULT; ARTICLE; BEDTIME DOSAGE; BLOOD PRESSURE MEASUREMENT; BODY DISTRIBUTION; BODY HEIGHT; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG WITHDRAWAL; ESTROGEN THERAPY; FEMALE; FOLLOW UP; FOOT; HORMONAL THERAPY; HUMAN; LONG TERM CARE; NORMAL VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TURNER SYNDROME;

BLOOD PRESSURE; BONE DENSITY; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; RECOMBINANT PROTEINS; TIME FACTORS; TURNER SYNDROME;

EID: 66449126916     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000223418     Document Type: Article

References (21)

1. Wit JM, Massarano AA, Kamp GA, Hind- marsh PC, van Es A, Brook CG, et al: Growth hormone secretion in patients with Turner's syndrome as determined by time series analysis. Acta Endocrinol (Copenh) 1992; 127:-712.
2. Van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ, et al: Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab 2003;88: 1119-1125.
3. Massa G, Heinrichs C, Verlinde S, Thomas M, Bourguignon JP, Craen M, et al: Late or delayed induced or spontaneous puberty in girls with Turner syndrome treated with growth hormone does not affect final height. J Clin Endocrinol Metab 2003; 88:4168-4174.
4. Soriano-Guillen L, Coste J, Ecosse E, Leger J, Tauber M, Cabrol S, et al: Adult height and pubertal growth in Turner syndrome after treatment with recombinant growth hormone. J ClinEndocrinol Metab2005;90:5197-5204.
5. Sas TC, Gerver WJ, de Bruin R, Stijnen T, de Muinck Keizer-Schrama SM, Cole TJ, et al: Body proportions during long-term growth hormone treatment in girls with Turner syndrome participating in a randomized dose- response trial. J Clin Endocrinol Metab 1999; 84:4622-4628.
6. Gravholt CH, Weis Naeraa R: Reference values for body proportions and body composition in adult women with Ullrich-Turner syndrome. Am J Med Genet 1997;72:403- 408.
7. Gerver WJ, Drayer NM, van Es A: Does growth hormone treatment of patients with Turner's syndrome cause an abnormal body shape? Acta Paediatr 1992;81:691-694.
8. Bannink EM, Raat H, Mulder PG, de Muinck Keizer-Schrama SM: Quality of life after growth hormone therapy and induced puberty in women with Turner syndrome. J Pe-diatr 2006; 148: 95-101.
9. Van den Berg J, Bannink EM, Wielopolski PA, Pattynama PM, de Muinck Keizer- Schrama SM, Helbing WA: Aortic distensi- bility and dimensions and the effects of growth hormone treatment in the Turner syndrome. Am J Cardiol 2006; 97: 1644-1649.
10. Bannink E, van der Palen R, Mulder P, de Muinck Keizer-Schrama S: Long-term follow-up of GH-treated girls with Turner syndrome: metabolic consequences. 2008 (submitted).
11. Task Force on Blood Pressure Control in Children, National Heart, Lung, and Blood Institute, Bethesda, Md: Report of the Second Task Force on Blood Pressure Control in Children, 1987. Pediatrics 1987;79:1-25.
12. Cameron N: The methods of auxological anthropometry; in Falkner F, Tanner JM (eds): Human Growth: Postnatal Growth. London, Tindall, 1978, pp 35-90.
13. Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, et al: Continuing positive secular growth change in the Netherlands 1955-1997. Pedi-atr Res 2000; 47: 316-323.
14. Elsheikh M, Conway GS: The impact of obesity on cardiovascular risk factors in Turner's syndrome. Clin Endocrinol (Oxf) 1998; 49: 447-450.
15. Ahmad AM, Hopkins MT, Weston PJ, Fraser WD, Vora JP: Effects of GH replacement on 24-hour ambulatory blood pressure and its circadian rhythm in adult GH deficiency. Clin Endocrinol (Oxf) 2002;56:431-437.
16. Smith JC, Evans LM, Wilkinson I, Goodfel- low J, Cockcroft JR, Scanlon MF, et al: Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin Endocrinol (Oxf) 2002; 56:493-501.
17. Blackett PR, Rundle AC, Frane J, Blethen SL: Body mass index in Turner syndrome before and during growth hormone therapy. Int J Obes Relat Metab Disord 2000; 24:232-235.
18. Sagi L, Zuckerman-Levin N, Gawlik A, Ghizzoni L, Buyukgebiz A, Rakover Y, et al: Clinical significance of the parental origin of the X-chromosome in Turner syndrome. J Clin Endocrinol Metab 2007; 92: 846-852.
19. Gravholt CH, Hjerrild BE, Weis Naeraa R, Engbaek F, Mosekilde L, Christiansen JS: Effect of growth hormone and 17ß-oestradiol treatment on metabolism and body composition in girls with Turner syndrome. Clin Endocrinol (Oxf) 2005; 62: 616-622.
20. Ari M, Bakalov VK, Hill S, Bondy CA: The effects of growth hormone treatment on bone mineral density and body composition in girls with Turner syndrome. J Clin Endo-crinol Metab 2006; 91: 4302-4305.
21. Van Pareren YK, De Muinck Keizer-Schra- ma SM, Stijnen T, Sas TC, Drop SL: Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with Turner syndrome. J Clin Endocrinol Metab 2002; 87: 5442-5448.